Treatment-Related Risk Factors for Diabetes Mellitus in Childhood Cancer Survivors-A Case-Cohort Study Within Adult Life After Childhood Cancer in Scandinavia (ALiCCS).

IF 2.4 3区医学 Q2 HEMATOLOGY

Pediatric Blood & Cancer Pub Date : 2025-05-21 DOI:10.1002/pbc.31805

Line Kenborg, Peter H Asdahl, Smita Bhatia, Jane Christensen, Thorgerdur Gudmundsdottir, Lars Hjorth, Rebecca Howell, Anja Krøyer, Morten Jørgensen, Michael R T Laursen, Yasmin Lassen-Ramshad, Sofie de Fine Licht, Thomas Tjørnelund Nielsen, Catherine Rechnitzer, Susan A Smith, Thomas Wiebe, Henrik Hasle, Anna S Holmqvist

{"title":"Treatment-Related Risk Factors for Diabetes Mellitus in Childhood Cancer Survivors-A Case-Cohort Study Within Adult Life After Childhood Cancer in Scandinavia (ALiCCS).","authors":"Line Kenborg, Peter H Asdahl, Smita Bhatia, Jane Christensen, Thorgerdur Gudmundsdottir, Lars Hjorth, Rebecca Howell, Anja Krøyer, Morten Jørgensen, Michael R T Laursen, Yasmin Lassen-Ramshad, Sofie de Fine Licht, Thomas Tjørnelund Nielsen, Catherine Rechnitzer, Susan A Smith, Thomas Wiebe, Henrik Hasle, Anna S Holmqvist","doi":"10.1002/pbc.31805","DOIUrl":null,"url":null,"abstract":"<p><p>The aim was to identify treatment-related risk factors for diabetes in 5-year survivors of childhood cancer (CCS). This case-cohort study within Adult Life after Childhood Cancer in Scandinavia (ALiCCS) included 140 CCS with diabetes and a subcohort of 390 randomly selected CCS. Incidence rate ratios (IRRs) and 95% confidence intervals (CIs) were calculated to assess the association between treatment exposures and diabetes. Radiotherapy was the most important risk factor, with increased IRR after total body irradiation (TBI) (9.8, 95% CI = 2.9-33.7), abdominal radiation (4.8, 95% CI = 2.2-10.4), and cranial radiation (4.3, 95% CI = 2.1-8.8). Continued follow-up with regard to diabetes is indicated after TBI, abdominal radiation, and cranial radiation in CCS.</p>","PeriodicalId":19822,"journal":{"name":"Pediatric Blood & Cancer","volume":" ","pages":"e31805"},"PeriodicalIF":2.4000,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric Blood & Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/pbc.31805","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

The aim was to identify treatment-related risk factors for diabetes in 5-year survivors of childhood cancer (CCS). This case-cohort study within Adult Life after Childhood Cancer in Scandinavia (ALiCCS) included 140 CCS with diabetes and a subcohort of 390 randomly selected CCS. Incidence rate ratios (IRRs) and 95% confidence intervals (CIs) were calculated to assess the association between treatment exposures and diabetes. Radiotherapy was the most important risk factor, with increased IRR after total body irradiation (TBI) (9.8, 95% CI = 2.9-33.7), abdominal radiation (4.8, 95% CI = 2.2-10.4), and cranial radiation (4.3, 95% CI = 2.1-8.8). Continued follow-up with regard to diabetes is indicated after TBI, abdominal radiation, and cranial radiation in CCS.

查看原文本刊更多论文

儿童癌症幸存者糖尿病的治疗相关危险因素——斯堪的纳维亚（ALiCCS）儿童癌症后成人生活中的病例队列研究

目的是确定5年儿童癌症幸存者（CCS）中糖尿病的治疗相关危险因素。这项斯堪的纳维亚儿童癌症后成人生活的病例队列研究（ALiCCS）包括140名患有糖尿病的CCS患者和390名随机选择的CCS亚队列。计算发病率比（IRRs）和95%置信区间（ci）来评估治疗暴露与糖尿病之间的关系。放射治疗是最重要的危险因素，全身放射（TBI）（9.8, 95% CI = 2.9-33.7）、腹部放射（4.8,95% CI = 2.2-10.4）和头部放射（4.3,95% CI = 2.1-8.8）后的IRR增加。在颅脑损伤、腹部放疗和颅脑放疗后，需要对糖尿病患者进行持续随访。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pediatric Blood & Cancer 医学-小儿科

CiteScore

4.90

自引率

9.40%

发文量

546

审稿时长

1.5 months

期刊介绍： Pediatric Blood & Cancer publishes the highest quality manuscripts describing basic and clinical investigations of blood disorders and malignant diseases of childhood including diagnosis, treatment, epidemiology, etiology, biology, and molecular and clinical genetics of these diseases as they affect children, adolescents, and young adults. Pediatric Blood & Cancer will also include studies on such treatment options as hematopoietic stem cell transplantation, immunology, and gene therapy.